Table 1

Vaccines administered, autoimmune diagnoses, immunosuppression and peri-vaccination management with longitudinal anti-spike antibody responses

Age	Sex	Diagnosis	Immunosuppressive therapy	Initial vaccine series	Meds held during initial vaccine	Pre-booster antibody	Booster vaccine type	Days from initial to booster vaccine	Post-booster antibody	Therapy held peri-booster*
39	F	Multiple sclerosis	Ocrelizumab	Pfizer	Yes	<0.40	J&J	60	<0.40	No
56	F	Mucous membrane pemphigoid	Mycophenolate	Pfizer	No	<0.40	J&J	47	<0.40	No
43	F	Inflammatory bowel disease†	Mycophenolate Tacrolimus	Pfizer	No	<0.40	Moderna	72	8.9	No
54	F	Myositis	Mycophenolate	Moderna	Yes	<0.40	J&J	98	205	Yes
53	F	Myositis	Methotrexate Hydroxychloroquine Prednisone	Moderna	Yes	<0.40	J&J	86	1111	Yes
56	M	Sarcoidoisis	Infliximab Mycophenolate Prednisone	Pfizer	NA‡	<0.40	Moderna	86	1276	Yes
44	F	SLE§	Belimumab Hydroxychloroquine Leflunomide Prednisone	J&J	No	<0.40	Moderna	91	2013	Yes
54	F	Sjogren’s syndrome	Azathioprine	J&J	NA‡	<0.40	Pfizer	36	>2500	Yes
75	M	Myositis	Mycophenolate	Pfizer	No	<0.40	Moderna	56	>2500	Yes
66	F	Inflammatory arthritis¶	Abatacept	J&J	No	<0.40	Pfizer	94	>2500	Yes
38	F	Myositis	Azathioprine Prednisone Tacrolimus	Moderna	No	2.7	Moderna	95	>2500	No
59	F	Myositis/scleroderma overlap	Hydroxychloroquine Mycophenolate Prednisone	Moderna	No	8.8	J&J	54	>2500	Yes
53	M	Myositis/inflammatory arthritis overlap	Hydroxychloroquine Mycophenolate	J&J	No	18.6	Pfizer	NA‡	>2500	Yes
72	F	Inflammatory arthritis¶	Methotrexate	Pfizer	No	222.7	J&J	95	>2500	Yes
64	F	Autoimmune hepatitis	Azathioprine Tacrolimus	Moderna	Yes	260	Moderna	83	>2500	Yes
44	M	Inflammatory bowel disease†	Golimumab Methotrexate	Pfizer	NA‡	359.8	Pfizer	68	>2500	Yes
75	F	Autoimmune hepatitis	Mycophenolate	Moderna	No	825.8	Moderna	96	>2500	No
57	M	Inflammatory arthritis¶	Secukinumab	Pfizer	Yes	2418	Moderna	54	>2500	Yes

*Median number (IQR) doses held for mycophenolate 27 (25–28). Fourteen doses of leflunomide held by one patient. Two doses of azathioprine held by two participants. One dose held for abatacept, belimumab, methotrexate and secukinumab respectively.
†Denotes Crohn’s disease or ulcerative colitis.
‡Denotes missing data.
§Systemic lupus erythematosus.
¶Rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, reactive arthritis or inflammatory bowel disease associated arthritis.
**Roche Elecsys anti-RBD pan-Ig ≥0.8 U/mL is considered positive (upper limit reported as >2500).